ACCRETION PHARMA LIMITED
Fundamental Score
ACCRETION PHARMA LIMITED Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ACCPL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (65.35%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (46.36%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 11.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (93.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (135.67%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (12.60x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (73.52%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Limited Institutional Interest (FII+DII: 1.16%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for ACCRETION PHARMA LIMITED
About ACCPL
Company Details
ACCPL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of ACCRETION PHARMA LIMITED (ACCPL)?
As of 29 Jan 2026, 10:39 am IST, ACCRETION PHARMA LIMITED (ACCPL) is currently trading at ₹67.40. The stock has a market capitalization of ₹103.05 (Cr).
Is ACCPL share price Overvalued or Undervalued?
ACCPL is currently trading at a P/E ratio of 11.35x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the ACCRETION PHARMA LIMITED share price?
Key factors influencing ACCPL's price include its quarterly earnings growth (Sales Growth: 135.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is ACCRETION PHARMA LIMITED a good stock for long-term investment?
ACCRETION PHARMA LIMITED shows a 5-year Profit Growth of N/A% and an ROE of 65.35%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing.
How does ACCRETION PHARMA LIMITED compare with its industry peers?
ACCRETION PHARMA LIMITED competes with major peers in the Pharmaceuticals. Investors should compare ACCPL's P/E of 11.35x and ROE of 65.35% against the industry averages to determine its competitive standing.
What is the P/E ratio of ACCPL and what does it mean?
ACCPL has a P/E ratio of 11.35x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹11 for every ₹1 of annual earnings.
How is ACCPL performing according to Bull Run's analysis?
ACCPL has a Bull Run fundamental score of 51.3/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ACCPL belong to?
ACCPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting ACCRETION PHARMA LIMITED.
What is Return on Equity (ROE) and why is it important for ACCPL?
ACCPL has an ROE of 65.35%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently ACCRETION PHARMA LIMITED generates profits from shareholders' equity.
How is ACCPL's debt-to-equity ratio and what does it indicate?
ACCPL has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ACCPL's dividend yield and is it a good dividend stock?
ACCPL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has ACCPL grown over the past 5 years?
ACCPL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ACCPL and why does it matter?
Promoters hold 73.52% of ACCPL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ACCPL's market capitalization category?
ACCPL has a market capitalization of ₹103 crores, placing it in the Small-cap category.
How volatile is ACCPL stock?
ACCPL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ACCPL?
ACCPL has a 52-week high of ₹N/A and low of ₹N/A.
What is ACCPL's operating profit margin trend?
ACCPL has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ACCPL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 135.67% and YoY Profit Growth of 93.09%.
What is the institutional holding pattern in ACCPL?
ACCPL has FII holding of 1.16% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.